Citations (89)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Karin Enell Smith, Adnan Deronic, Karin Hägerbrand, Per Norlén & Peter Ellmark. (2021) Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy. Expert Opinion on Biological Therapy 21:12, pages 1635-1646.
Read now
Read now
Mariona Cabo, Rienk Offringa, Laurence Zitvogel, Guido Kroemer, Aura Muntasell & Lorenzo Galluzzi. (2017) Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. OncoImmunology 6:12.
Read now
Read now
Anna Korycka-Wołowiec, Dariusz Wołowiec & Tadeusz Robak. (2017) The safety profile of monoclonal antibodies for chronic lymphocytic leukemia. Expert Opinion on Drug Safety 16:2, pages 185-201.
Read now
Read now
Joseph M. Ryan, Jeffrey S. Wasser, Adam J. Adler & Anthony T. Vella. (2016) Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. Expert Opinion on Biological Therapy 16:5, pages 655-674.
Read now
Read now
Linlin Jiang, Ming Yang, Xiaoyun Zhang, Shiqi Bao, Li Ma, Dongmei Fan, Yuan Zhou, Dongsheng Xiong & Yongsu Zhen. (2016) A novel antibody–drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity. Journal of Drug Targeting 24:1, pages 47-57.
Read now
Read now
Michael Doubek & Michal Šmída. (2015) Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?. Expert Review of Hematology 8:6, pages 743-764.
Read now
Read now
Pawel Robak, Piotr Smolewski & Tadeusz Robak. (2015) Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opinion on Emerging Drugs 20:3, pages 423-447.
Read now
Read now
Tadeusz Robak. (2014) Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. Expert Review of Hematology 7:6, pages 841-857.
Read now
Read now
Sufia Butt Hassan, Jesper Freddie Sørensen, Barbara Nicola Olsen & Anders Elm Pedersen. (2014) Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacology and Immunotoxicology 36:2, pages 96-104.
Read now
Read now
Fernando Aranda, Erika Vacchelli, Alexander Eggermont, Jérôme Galon, Wolf Hervé Fridman, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch. OncoImmunology 3:2.
Read now
Read now
Loretta J Nastoupil, Rajni Sinha & Christopher R Flowers. (2013) The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy. Expert Review of Anticancer Therapy 13:9, pages 1089-1108.
Read now
Read now
John C. Byrd, Thomas J. Kipps, Ian W. Flinn, Maureen Cooper, Olatoyosi Odenike, Jennifer Bendiske, John Rediske, Sanela Bilic, Jyotirmoy Dey, Johan Baeck & Susan O’Brien. (2012) Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leukemia & Lymphoma 53:11, pages 2136-2142.
Read now
Read now
Aisha Masood, Taimur Sher, Aneel Paulus, Kena C Miller, Kasyapa S Chitta & Asher Chanan-Khan. (2011) Targeted treatment for chronic lymphocytic leukemia. OncoTargets and Therapy 4, pages 169-183.
Read now
Read now
Chadi Nabhan, Neil Dalal, Jayesh Mehta & Neil E. Kay. (2011) Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies. Leukemia & Lymphoma 52:3, pages 374-386.
Read now
Read now
Articles from other publishers (75)
Qian Yang, Hong Jiang, Yue Wang, Xiao Leng, Yantang Wang, Jie Tong, Yang Zhou, Chunfen Mo, Jinrong Peng & Huile Gao. (2023) Plaque Macrophage‐Targeting Nanosystems with Cooperative Co‐Regulation of ROS and TRAF6 for Stabilization of Atherosclerotic Plaques. Advanced Functional Materials 33:28.
Crossref
Crossref
Hsuan‐Chen Liu, Daniel Davila Gonzalez, Dixita Ishani Viswanath, Robin Shae Vander Pol, Shani Zakiya Saunders, Nicola Di Trani, Yitian Xu, Junjun Zheng, Shu‐Hsia Chen, Corrine Ying Xuan Chua & Alessandro Grattoni. (2023) Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. Advanced Science 10:9.
Crossref
Crossref
Victor Moreno, Ruth Perets, Tamar Peretz-Yablonski, Nele Fourneau, Suzette Girgis, Yue Guo, Peter Hellemans, Raluca Verona, Natalia Pendás, Qi Xia, Ravit Geva & Emiliano Calvo. (2022) A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors. Investigational New Drugs 41:1, pages 93-104.
Crossref
Crossref
Tae Kon Kim, Esten N. Vandsemb, Roy S. Herbst & Lieping Chen. (2022) Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nature Reviews Drug Discovery 21:7, pages 529-540.
Crossref
Crossref
Ran Salomon, Hagar Rotem, Yonatan Katzenelenbogen, Assaf Weiner, Noy Cohen Saban, Tali Feferman, Ido Amit & Rony Dahan. (2022) Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting. Nature Cancer 3:3, pages 287-302.
Crossref
Crossref
Laura A. Huppert, Ozge Gumusay & Hope S. Rugo. (2022) Emerging treatment strategies for metastatic triple-negative breast cancer. Therapeutic Advances in Medical Oncology 14, pages 175883592210869.
Crossref
Crossref
Laura A. Huppert, Veronica Mariotti, A. Jo Chien & Hatem H. Soliman. (2021) Emerging immunotherapeutic strategies for the treatment of breast cancer. Breast Cancer Research and Treatment 191:2, pages 243-255.
Crossref
Crossref
Oksana Raabe, Thomas Birchler, Hubert Rehrauer & Elisabeth Eppler. (2021) CD40 Agonist Monoclonal Antibody-Mediated Hepatitis in TNF-Receptor 1 Gene Knockout Mice. Biomedicines 9:8, pages 863.
Crossref
Crossref
Raquel Delgado, Karoline Kielbassa, Johanna ter Burg, Christian Klein, Christine Trumpfheller, Koen de Heer, Arnon P. Kater & Eric Eldering. (2021) Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia. Cancers 13:12, pages 3084.
Crossref
Crossref
Christopher S. Garris, Jeffrey L. Wong, Jeffrey V. Ravetch & David A. Knorr. (2021) Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer. Science Translational Medicine 13:594.
Crossref
Crossref
Clifford M. Csizmar & Stephen M. Ansell. (2021) Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma. International Journal of Molecular Sciences 22:7, pages 3302.
Crossref
Crossref
TingTing Tang, Xiang Cheng, Billy Truong, LiZhe Sun, XiaoFeng Yang & Hong Wang. (2021) Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. Pharmacology & Therapeutics 219, pages 107709.
Crossref
Crossref
John W. Myers, George E. Peoples & Guy T. Clifton. 2021. Cancer Immunology. Cancer Immunology
85
128
.
Anne Bordron, Cristina Bagacean, Adrian Tempescul, Christian Berthou, Eléonore Bettacchioli, Sophie Hillion & Yves Renaudineau. (2019) Complement System: a Neglected Pathway in Immunotherapy. Clinical Reviews in Allergy & Immunology 58:2, pages 155-171.
Crossref
Crossref
Simone Ragusa, Borja Prat-Luri, Alejandra González-Loyola, Sina Nassiri, Mario Leonardo Squadrito, Alan Guichard, Sabrina Cavin, Nikolce Gjorevski, David Barras, Giancarlo Marra, Matthias P. Lutolf, Jean Perentes, Emily Corse, Roberta Bianchi, Laureline Wetterwald, Jaeryung Kim, Guillermo Oliver, Mauro Delorenzi, Michele De Palma & Tatiana V. Petrova. (2020) Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice. Journal of Clinical Investigation 130:3, pages 1199-1216.
Crossref
Crossref
Li Lu, Xi Wang, Ao Zhang, Fei Huang, Yongjia Yan, Weidong Li & Weihua Fu. (2019) Selection and expression of CD40 single chain variable fragment by phage display and evaluation of tumor specific immune activation. International Immunopharmacology 71, pages 224-232.
Crossref
Crossref
Ali A. Maawy & Fumito Ito. 2019. Immune Checkpoint Inhibitors in Cancer. Immune Checkpoint Inhibitors in Cancer
227
243
.
Victor Navarro-Tableros, Yonathan Gomez, Giovanni Camussi & Maria Felice Brizzi. (2018) Extracellular Vesicles: New Players in Lymphomas. International Journal of Molecular Sciences 20:1, pages 41.
Crossref
Crossref
Carlos Cuesta-Mateos, Ana Alcaraz-Serna, Beatriz Somovilla-Crespo & Cecilia Muñoz-Calleja. (2018) Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets. Frontiers in Immunology 8.
Crossref
Crossref
Xiaojie Yu, Michael J. E. Marshall, Mark S. Cragg & Max Crispin. (2017) Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering. BioDrugs 31:3, pages 151-166.
Crossref
Crossref
Iulia Giuroiu & Jeffrey Weber. (2017) Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy. The Cancer Journal 23:1, pages 23-31.
Crossref
Crossref
David Kotlyar & Anthony Leonardi. 2017. Cancer Therapeutic Targets. Cancer Therapeutic Targets
31
42
.
Yu Zhan, Yilei Wei, Pengfei Chen, Haohao Zhang, Dandan Liu, Jie Zhang, Rongzeng Liu, Ran Chen, Jun Zhang, Wei Mo & Xiaoren Zhang. (2016) Expression, purification and biological characterization of the extracellular domain of CD40 from Pichia pastoris. BMC Biotechnology 16:1.
Crossref
Crossref
Matthijs F. Jansen, Maurits R. Hollander, Niels van Royen, Anton J. Horrevoets & Esther Lutgens. (2016) CD40 in coronary artery disease: a matter of macrophages?. Basic Research in Cardiology 111:4.
Crossref
Crossref
Rony Dahan, Bryan C. Barnhart, Fubin Li, Aaron P. Yamniuk, Alan J. Korman & Jeffrey V. Ravetch. (2016) Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement. Cancer Cell 29:6, pages 820-831.
Crossref
Crossref
Tadeusz Robak, Jerzy Z. Blonski & Pawel Robak. (2016) Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia. Seminars in Oncology 43:2, pages 280-290.
Crossref
Crossref
Ciara L. Freeman & John G. Gribben. (2016) Immunotherapy in Chronic Lymphocytic Leukaemia (CLL). Current Hematologic Malignancy Reports 11:1, pages 29-36.
Crossref
Crossref
Shengdian Wang & Mingming Jia. 2016. Progress in Cancer Immunotherapy. Progress in Cancer Immunotherapy
1
67
.
David Kotlyar & Anthony Leonardi. 2016. Cancer Therapeutic Targets. Cancer Therapeutic Targets
1
12
.
Preetesh Jain & Susan O'Brien. 2015. Targeted Therapy in Translational Cancer Research. Targeted Therapy in Translational Cancer Research
130
144
.
Elizabeth A. Thompson, Frank Liang, Gustaf Lindgren, Kerrie J. Sandgren, Kylie M. Quinn, Patricia A. Darrah, Richard A. Koup, Robert A. Seder, Ross M. Kedl & Karin Loré. (2015) Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates. The Journal of Immunology 195:3, pages 1015-1024.
Crossref
Crossref
Sjoukje J. C. van der Stegen, Mohamad Hamieh & Michel Sadelain. (2015) The pharmacology of second-generation chimeric antigen receptors. Nature Reviews Drug Discovery 14:7, pages 499-509.
Crossref
Crossref
Dmitriy Zamarin & Michael A. Postow. (2015) Immune checkpoint modulation: Rational design of combination strategies. Pharmacology & Therapeutics 150, pages 23-32.
Crossref
Crossref
Ghada S. Hassan, John Stagg & Walid Mourad. (2015) Role of CD154 in cancer pathogenesis and immunotherapy. Cancer Treatment Reviews 41:5, pages 431-440.
Crossref
Crossref
Alexander M. LesokhinMargaret K. CallahanMichael A. PostowJedd D. Wolchok. (2015) On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Science Translational Medicine 7:280.
Crossref
Crossref
Manzoor Ahmad Mir. 2015. Developing Costimulatory Molecules for Immunotherapy of Diseases. Developing Costimulatory Molecules for Immunotherapy of Diseases
185
254
.
Brianna Oliver, Erica Jackson & Hatem Soliman. 2015. Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies. Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies
411
431
.
Guy T. Clifton, Elizabeth A. Mittendorf & George E. Peoples. 2015. Cancer Immunology. Cancer Immunology
87
129
.
Tejas Suresh, Lisa X Lee, Jitesh Joshi & Stefan K Barta. (2014) New antibody approaches to lymphoma therapy. Journal of Hematology & Oncology 7:1.
Crossref
Crossref
Eric L. Smith, Dmitriy Zamarin & Alexander M. Lesokhin. (2014) Harnessing the immune system for cancer therapy. Current Opinion in Oncology 26:6, pages 600-607.
Crossref
Crossref
Stephanie R Jackson, Jinyun Yuan & Ryan M Teague. (2014)
Targeting CD8
+
T-cell tolerance for cancer immunotherapy
. Immunotherapy 6:7, pages 833-852.
Crossref
Crossref
Christian P. Pallasch & Michael Hallek. (2014) Incorporating Targeted Agents Into Future Therapy of Chronic Lymphocytic Leukemia. Seminars in Hematology 51:3, pages 235-248.
Crossref
Crossref
Sandrine T. Lafarge, James B. Johnston, Spencer B. Gibson & Aaron J. Marshall. (2014) Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway. Leukemia Research 38:1, pages 109-115.
Crossref
Crossref
Marcus Remer, Ann White, Martin Glennie, Aymen Al-Shamkhani & Peter Johnson. 2017. Cancer Vaccines. Cancer Vaccines
165
207
.
Michael Hallek. (2013) Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Hematology 2013:1, pages 138-150.
Crossref
Crossref
Michael Hallek. (2013) Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood 122:23, pages 3723-3734.
Crossref
Crossref
Michael Hallek. (2013) Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. American Journal of Hematology 88:9, pages 803-816.
Crossref
Crossref
John C. Riches & John G. Gribben. (2013) Understanding the Immunodeficiency in Chronic Lymphocytic Leukemia. Hematology/Oncology Clinics of North America 27:2, pages 207-235.
Crossref
Crossref
Deborah M. Stephens & John C. Byrd. (2013) Improving the Treatment Outcome of Patients with Chronic Lymphocytic Leukemia Through Targeted Antibody Therapy. Hematology/Oncology Clinics of North America 27:2, pages 303-327.
Crossref
Crossref
Amy E Moran, Magdalena Kovacsovics-Bankowski & Andrew D Weinberg. (2013) The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Current Opinion in Immunology 25:2, pages 230-237.
Crossref
Crossref
Ignacio Melero, Antonio M. Grimaldi, Jose L. Perez-Gracia & Paolo A. Ascierto. (2013) Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination. Clinical Cancer Research 19:5, pages 997-1008.
Crossref
Crossref
Robert H. Vonderheide & Martin J. Glennie. (2013) Agonistic CD40 Antibodies and Cancer Therapy. Clinical Cancer Research 19:5, pages 1035-1043.
Crossref
Crossref
Michael Croft, Chris A. Benedict & Carl F. Ware. (2013) Clinical targeting of the TNF and TNFR superfamilies. Nature Reviews Drug Discovery 12:2, pages 147-168.
Crossref
Crossref
Tadeusz Robak. (2013) Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. Future Oncology 9:1, pages 69-91.
Crossref
Crossref
Shirley G K Seah, Jamie L Brady, Emma M Carrington, Wy Ching Ng, Robyn M Sutherland, Manuela S Hancock, Nicole L La Gruta, Lorena E Brown, Stephen J Turner, Andrew M Lew & Yifan Zhan. (2013) Influenza-induced, helper-independent CD8+ T cell responses use CD40 costimulation at the late phase of the primary response. Journal of Leukocyte Biology 93:1, pages 145-154.
Crossref
Crossref
Heidemarie Gast, Andreas Müller, Martin Lopez, Daniel Meier, Reto Huber, Frieder Dechent, Marco Prinz, Yann Emmenegger, Paul Franken, Thomas Birchler & Adriano Fontana. (2013) CD40 activation induces NREM sleep and modulates genes associated with sleep homeostasis. Brain, Behavior, and Immunity 27, pages 133-144.
Crossref
Crossref
Margaret K. Callahan, Jedd D. Wolchok, James P. Allison & Padmanee Sharma. 2013. Cancer Immunotherapy. Cancer Immunotherapy
211
280
.
Rotem Kedar, Ofra Sabag, Michal Licthenstein & Haya Lorberboum‐Galski. (2012) Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment. Cancer 118:24, pages 6089-6104.
Crossref
Crossref
Kang Lu & Xin Wang. (2012) Therapeutic advancement of chronic lymphocytic leukemia. Journal of Hematology & Oncology 5:1.
Crossref
Crossref
John M. Kirkwood, Lisa H. Butterfield, Ahmad A. Tarhini, Hassane Zarour, Pawel Kalinski & Soldano Ferrone. (2012) Immunotherapy of cancer in 2012. CA: A Cancer Journal for Clinicians 62:5, pages 309-335.
Crossref
Crossref
Tadeusz Robak. (2012) Przeciwciała monoklonalne w leczeniu przewlekłej białaczki limfocytowej. Acta Haematologica Polonica 43:2, pages 99-106.
Crossref
Crossref
Juan Ma, Yoshihiko Usui, Takeshi Kezuka, Yoko Okunuki, Lina Zhang, Xiaoming An, Atsushi Mizota & Hiroshi Goto. (2012) Costimulatory molecule expression on human uveal melanoma cells: Functional analysis of CD40 and B7-H1. Experimental Eye Research 96:1, pages 98-106.
Crossref
Crossref
Daria Capece, Daniela Verzella, Mariafausta Fischietti, Francesca Zazzeroni & Edoardo Alesse. (2012) Targeting Costimulatory Molecules to Improve Antitumor Immunity. Journal of Biomedicine and Biotechnology 2012, pages 1-17.
Crossref
Crossref
D. Spoerl & Andreas J. Bircher. 2012. A worldwide yearly survey of new data in adverse drug reactions and interactions. A worldwide yearly survey of new data in adverse drug reactions and interactions
579
607
.
Andrew Weinberg, Robert H. Vonderheide & Mario Sznol. 2012. Targeted Therapeutics in Melanoma. Targeted Therapeutics in Melanoma
307
331
.
Jonathan A. Gutman, Kelly M. Smith, John M. Pagel & John M. Pagel. 2012. Leukemia and Related Disorders. Leukemia and Related Disorders
67
96
.
Veronique Blanc, Anne Bousseau, Anne Caron, Chantal Carrez, Robert J. Lutz & John M. Lambert. (2011) SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies. Clinical Cancer Research 17:20, pages 6448-6458.
Crossref
Crossref
I. García-Escobar, J. Sepúlveda, D. Castellano & H. Cortés-Funes. (2011) Therapeutic management of chronic lymphocytic leukaemia. Critical Reviews in Oncology/Hematology 80:1, pages 100-113.
Crossref
Crossref
Chuda Chittasupho, Teruna J SiahaanCharlotte M Vines & Cory Berkland. (2011) Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics. Therapeutic Delivery 2:7, pages 873-889.
Crossref
Crossref
Tom van Meerten & Anton Hagenbeek. (2011) Novel antibodies against follicular non-Hodgkin’s lymphoma. Best Practice & Research Clinical Haematology 24:2, pages 231-256.
Crossref
Crossref
P. Thompson, K. Cardona, M. Russell, I.R. Badell, V. Shaffer, G. Korbutt, G.R. Rayat, J. Cano, M. Song, W. Jiang, E. Strobert, R. Rajotte, T. Pearson, A.D. Kirk & C.P. Larsen. (2011) CD40-Specific Costimulation Blockade Enhances Neonatal Porcine Islet Survival in Nonhuman Primates. American Journal of Transplantation 11:5, pages 947-957.
Crossref
Crossref
Cornelia Taraborrelli, Svitlana Palchykova, Irene Tobler, Heidemarie Gast, Thomas Birchler & Adriano Fontana. (2011) TNFR1 is essential for CD40, but not for lipopolysaccharide-induced sickness behavior and clock gene dysregulation. Brain, Behavior, and Immunity 25:3, pages 434-442.
Crossref
Crossref
Roch Houot, Holbrook Kohrt, Matthew J. Goldstein & Ronald Levy. (2011) Immunomodulating antibodies and drugs for the treatment of hematological malignancies. Cancer and Metastasis Reviews 30:1, pages 97-109.
Crossref
Crossref
Samantha M. Jaglowski, Lapo Alinari, Rosa Lapalombella, Natarajan Muthusamy & John C. Byrd. (2010) The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 116:19, pages 3705-3714.
Crossref
Crossref
Ester Fonsatti, Michele Maio, Maresa Altomonte & Peter Hersey. (2010) Biology and Clinical Applications of CD40 in Cancer Treatment. Seminars in Oncology 37:5, pages 517-523.
Crossref
Crossref